Skip to content

Endometrial Preparation in Frozen Embryo Transfer Cycles

Hormonal Replacement Therapy Plus Letrozole Incorporation Versus Letrozole Mild Ovarian Stimulation in Endometrial Preparation for Frozen Embryo Transfer: A Randomised Controlled Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06181305
Enrollment
210
Registered
2023-12-26
Start date
2024-02-24
Completion date
2024-12-25
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF

Brief summary

In order to get optimal pregnancy rates after frozen embryo transfer (FET), the embryo stage and endometrium should be synchronized. Endometrial preparation is done by either natural, artificial (Hormonal replacement therapy HRT) , modified natural methods or mild ovarian stimulation. HRT cycle has a better schedualization however, there are some reports about higher rates of miscarriage, pregnancy induced hypertension (PIH) and preeclampsia (PET) in HRT cycles. A recent study has found that incorporation of the aromatase inhibitor (letrozole) to HRT cycles was associated with better FET outcomes in comparison to hormonal replacement therapy cycles alone. Meanwhile, mild ovarian stimulation protocol can be done either by oral drugs like letrozole or by letrozole plus gonadotropins . So this study aims to compare the reproductive outcomes in two endometrial preparation protocols for frozen embryo transfer cycles; letrozole mild ovarian stimulation versus HRT plus letrozole incorporation.

Detailed description

In order to get optimal pregnancy rates after frozen embryo transfer (FET), the embryo stage and endometrium should be synchronized. This can be done by hormonal replacement therapy (HRT), natural cycles (NC), modified natural cycles or mild ovarian stimulation. In hormonal replacement therapy cycle, estrogen and progesterone are sequentially given to resemble the hormonal course of the natural cycle . Hormonal replacement therapy cycle has a better schedualization and is used for patients with irregular cycles as polycystic ovary syndrome ( PCOS). However, there are some reports about higher rates of miscarriage, pregnancy induced hypertension (PIH) and preeclampsia (PET) in HRT cycles. A recent study has found that incorporation of the aromatase inhibitor (letrozole) to HRT cycles was associated with better FET outcomes in comparison to HRT cycles alone. Ongoing pregnancy rate (OPR) was higher in HRT plus letrozole group than HRT only group. Letrozole is a third-generation aromatase inhibitor that leads to mono-ovulatory cycles with short half-life . Miller and his colleagues found that letrozole increased Integrin expression and improved pregnancy and implantation rates among women with endometrial receptivity defects . Another study found that ovarian stimulation with letrozole was associated with increase in the expression of uterine receptivity markers including integrin, leukemia inhibitory factor, and L-selectin.

Interventions

DRUGestradiol valerate and letrozole

hormone replacement therapy by estradiol valerate plus letrozole incorporation .

DRUGletrozole 2,5 mg tablet

mild ovarian stimulation

Sponsors

Rahem Fertility Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

* Women aged between 18 and 37 years with either regular cycles or oligomenorrhoea or amenorrhoea. * Women undergoing FET cycles. * Participants should have at least one good-quality blastocyst available for vitrification and also for transfer after warming. * Participants having optimal endometrium before starting luteal phase support

Exclusion criteria

* Women who will refuse to participate in in the study. * Women who will not reach the optimal endometrium. * Participants that don't have at least one good-quality blastocyst for transfer after warming. * PGT embryos will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
ongoing pregnancy rate (OPR)12 weeksNumber of pregnant women with viable fetus at 12 weeks gestation per woman randomized

Secondary

MeasureTime frameDescription
Ectopic pregnancy7 weekpregnancy outside the uterine cavity diagnosed by ultrasound ,surgical visualization or histopathology
Miscarriage rate12 weeksNumber of miscarriages per woman with positive pregnancy tests
Implantation rate21 days after embryo transferNumber of gestational sac recognized by ultrasound in uterus 3 weeks after embryo transfer
Clinical pregnancy rate (CPR)5 weeks after embryo transferNumber of gestational sacs with evident fetal pulsations per woman randomized,ectopic pregnancy is also includded pregnancy is aslo included
Number of participants with Hypertensive disorders of pregnancy20 weeks gestation till postpartumgestational hypertension or preeclampsia
Number of participants with Large for gestational agefrom gestation till deliveryA birth weight greater than the 90th centile of the sex-specific birth weight for a given gestational age reference
live birth rate22 completed weeks of gestational ageThe complete expulsion or extraction from a woman of a product of fertilization,after 22 complete weeks of gestational age;which,after such separation,breathes or shows any other evidence of life,such as heart beat,umblical cord pulsation or definite movement of voluntary muscles,irrespective of whether the umblical cord has been cut or the placenta is attached.A birth weight of 500 grams or more can be used if gestational age is unknown.Live births refer to the individual newborn ;for example,a twin delivery represents two live births

Countries

Egypt

Contacts

Primary ContactNoha Moustafa El-hibishy, MSc
nohaesmaeelobgyn@yahoo.com00201067411131
Backup ContactEman El-gindy, MD,PhD
eman_elgindy2013@hotmail.com00201227491143

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026